metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population 5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative 1
mNSCLC - L1 - PDL1 positive 14
mNSCLC - L1 - TMB>10Mb 1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population 3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT) 6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population 4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus paclitaxel

versus all
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs atezolizumab based treatment
vs atezolizumab plus carboplatin plus nab-paclitaxel
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs bevacizumab plus carboplatin and paclitaxel

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open